Navigation Links
Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
Date:9/18/2007

INDIANAPOLIS, Sept. 18 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that Robert J. Heine, M.D., Ph.D., F.R.C.P., will join Lilly in January, 2008, as Executive Medical Director for the Diabetes and Endocrine division responsible for development of Lilly's expanding diabetes and obesity R&D portfolio. Dr. Heine replaces Dr. Meng Hee Tan, Distinguished Medical Fellow, Diabetes and Endocrine, who will retire at the end of September after 8 years of outstanding service to the company.

"Lilly has a growing and exciting diabetes and obesity R&D portfolio that demands exceptional clinical leadership to guide and successfully develop," said Vince Mihalik, Vice President and Global Brand Development Platform Leader, Diabetes, Obesity and Endocrine. "Robert is widely recognized and respected in the diabetes community for his scientific and clinical excellence and his considerable leadership abilities. He'll be a fantastic addition to the Lilly team."

Heine is currently professor of diabetology in the Department of Endocrinology and director of the Diabetes Centre at the VU (Vrije Universiteit) University Medical Center in Amsterdam, Netherlands. In addition to involvement in several research projects, Heine holds positions within the European Association for the Study of Diabetes (EASD), the European Foundation for the Study of Diabetes (EFSD) and the American Diabetes Association (ADA), including chair of the EASD subcommittee for Clinical Research Training, president of the organizing committee for the 2007 EASD annual meeting, and a member of the ADA Expert Committee on guidelines for the treatment of hyperglycemia in type 2 diabetes. He is a prolific author, with more than 350 published papers, and currently serves as associate editor of Diabetic Medicine and an editorial board member for several other publications. Heine's primary research interests include the epidemiology and pathophysiology of type 2 diabetes.

"We couldn't be more pleased that Dr. Heine has decided to bring his considerable talents to Lilly," said David Moller, M.D., Vice President, Endocrine and Cardiovascular Research and Clinical Investigation, Lilly Research Laboratories. "Robert's outstanding clinical experience and depth of scientific expertise will be a major contributor to the sustained leadership of Lilly in diabetes and related metabolic disorders as we continue to bring novel medicines to patients in need around the world."

"It's a privilege to join a team with such an impressive history of innovation and one that is also shaping the future of diabetes care," said Heine. "I'm excited for the opportunity to work in a new and dynamic atmosphere at Lilly with a group of truly talented scientists."

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.

C-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Crohns Patient Robert Hill’s greatest achievemen
2. Relapse in Risk Management System Claims the Life of Robertson
3. Robert Wood Johnson Foundation Pledges $500M To Fund Anti-Obesity Programs
4. Distinguished Scientist Award Conferred on Manchester Dentist
5. Distinguished Scientist Award Conferred on University of Rochester Scientists for Work on Preventing Cavities
6. Is Diabetes the Leading Cause of Kidney Failure in India
7. Diabetes and Depression often go hand-in-hand
8. Vitamin E, the latest warrior against diabetes
9. Thirty minutes of work up per day reduces the risk of Diabetes
10. New Drug for Diabetes
11. Diabetes, obesity rates shooting up
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Altamonte Springs, FL (PRWEB) , ... February 09, ... ... nation’s leading innovative specialty pharmacies, announces today the continuation of the ‘Pay It ... donations for each prescription referral received at our specialty pharmacy. , “Since ...
(Date:2/9/2016)... ... February 09, 2016 , ... Dr. Rassouli, cosmetic dentist in Orange ... among the most popular cosmetic procedures in dentistry today, but the cost often leads ... them at risk of teeth whitening-related damage. For a limited time, Dr. Rassouli is ...
(Date:2/9/2016)... ... ... United Methodist Communications collaborated with Chocolate Moose Media and ... designed to prevent the next widespread Ebola outbreak from occurring in West ... Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire and other African countries, with additional ...
(Date:2/8/2016)... ... 2016 , ... CURE Media Group , the nation’s leading digital and ... Heroes Awards event , which will annually honor individuals making heroic contributions in the ... MM Heroes Awards nomination process is officially open through February 17 for ...
(Date:2/8/2016)... Texas (PRWEB) , ... February 08, 2016 , ... The Valentine’s Season is famous for ... members and significant others that they are loved. This year, for more than 5.6 ... they cost - just won't be enough to remind them of the lives they’ve led ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)...  Landauer, Inc. (NYSE: LDR ), a recognized ... outsourced medical physics services and high quality medical consumable ... first quarter ended December 31, 2015. ... Quarter Highlights , Revenue of $36.5 million compared ... , Domestic Radiation Measurement services revenues increased 2.8% year-over-year ...
(Date:2/9/2016)... Calif., Feb. 9, 2016  Sangamo BioSciences, Inc. ... genome editing, today reported its fourth quarter and ... in vivo therapeutic genome editing," said ... "Our zinc finger nuclease (ZFN) technology leads the ... the core competencies necessary to move our ground-breaking ...
(Date:2/9/2016)... , February 9, 2016 ... a collaboration with 10x Genomics to develop and ... biology and bioinformatics. --> QGEN ; ... with 10x Genomics to develop and promote comprehensive ... bioinformatics. --> QIAGEN N.V. (NASDAQ: ...
Breaking Medicine Technology: